Spironolactone Tablet, Film Coated
Product Images NDC 55154-3556

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 55154-3556). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bag Label (96db5dee 7c01 4f96 8b1e 1fcd2103d0fe 00)

Spironolactone Tablets, USP 25 mg film-coated tablets in a package of 10 tablets. The label includes storage instructions to keep at 20° to 25°C, warnings about child resistance, and references to an insert for full prescribing information. Manufactured by Cadila Healthcare Ltd, India, and distributed by Zydus Pharmaceuticals (USA) Inc., Major Pharmaceuticals, and Cardinal Health.*

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 01)

Chemical structure of spironolactone, depicting its steroid-like fused ring system with characteristic functional groups including a thioester moiety. The diagram illustrates the molecular structure relevant to this active ingredient in the product.*

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 02)

A Kaplan-Meier survival probability curve comparing spironolactone (n=822) and placebo (n=841) over a period of 48 months. The y-axis represents probability ranging from 0.0 to 1.0, and the x-axis represents time in months. The spironolactone group shows higher survival probability throughout the timeline, with a log-rank p-value of less than 0.001 included on the graph.*

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 03)

A forest plot comparing hazard ratios (HR) with 95% confidence intervals (CI) across various subgroups such as age, sex, race, left ventricular ejection fraction, heart failure type, NYHA class, diabetes status, serum creatinine levels, creatinine clearance, potassium levels, and medication use. The x-axis shows the comparison between spironolactone and placebo effectiveness, with HR centered around 1 and subgroup sizes (N) and percentages listed on the right.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.